M&T Bank Corp Lowers Position in IQVIA Holdings Inc. (NYSE:IQV)

M&T Bank Corp lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,410 shares of the medical research company's stock after selling 25,851 shares during the period. M&T Bank Corp's holdings in IQVIA were worth $16,448,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Continuum Advisory LLC increased its position in IQVIA by 13.1% during the 3rd quarter. Continuum Advisory LLC now owns 1,739 shares of the medical research company's stock worth $412,000 after purchasing an additional 201 shares in the last quarter. LRI Investments LLC boosted its holdings in shares of IQVIA by 3,542.7% during the 3rd quarter. LRI Investments LLC now owns 23,823 shares of the medical research company's stock valued at $5,645,000 after acquiring an additional 23,169 shares in the last quarter. Drucker Wealth 3.0 LLC grew its position in IQVIA by 1.4% during the 3rd quarter. Drucker Wealth 3.0 LLC now owns 9,260 shares of the medical research company's stock worth $2,194,000 after acquiring an additional 124 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its position in IQVIA by 7.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 54,164 shares of the medical research company's stock valued at $12,835,000 after purchasing an additional 3,872 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its stake in shares of IQVIA by 1.8% during the third quarter. Y Intercept Hong Kong Ltd now owns 14,950 shares of the medical research company's stock valued at $3,543,000 after purchasing an additional 270 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. The Goldman Sachs Group cut their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their price target on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Finally, Truist Financial cut their price objective on IQVIA from $265.00 to $261.00 and set a "buy" rating on the stock in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $255.82.

IQVIA Stock Up 3.0 %

NYSE:IQV traded up $5.75 on Friday, hitting $197.27. The stock had a trading volume of 3,345,878 shares, compared to its average volume of 1,204,975. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The business's fifty day moving average is $208.90 and its 200 day moving average is $223.32. The company has a market cap of $35.80 billion, a PE ratio of 25.89, a P/E/G ratio of 2.05 and a beta of 1.49.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.